Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Mosquito-Borne Viral Diseases. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Mosquito-Borne Viral Diseases (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 106 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Dengue Vaccines

A vaccine is urgently needed to control dengue. There are at least five candidate vaccines in clinical trials and research. The World Health Organization (WHO) Strategic Advisory Group of experts on immunization recommended the first dengue vaccine, Dengvaxia, registered in Mexico in December 2015, only be used in geographic areas with a high endemicity. This vaccine is a tetravalent live recombinant vaccine given in three doses. It is only given to people age 9-45 years who live where dengue is endemic; therefore, younger patients and tourists are not eligible. The US National Institutes of Health (NIH) has started clinical trials on another live attenuated tetravalent vaccine that only requires one injection. It was reported effective in a small trial.